nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—Breast Cancer Resistance Protein Inhibitors—Ritonavir—acquired immunodeficiency syndrome	0.168	0.267	CiPCiCtD
Dabrafenib—Cytochrome P450 2B6 Inducers—Nevirapine—acquired immunodeficiency syndrome	0.14	0.222	CiPCiCtD
Dabrafenib—Cytochrome P450 2C19 Inducers—Ritonavir—acquired immunodeficiency syndrome	0.112	0.178	CiPCiCtD
Dabrafenib—Cytochrome P450 2B6 Inducers—Efavirenz—acquired immunodeficiency syndrome	0.112	0.178	CiPCiCtD
Dabrafenib—Cytochrome P450 3A4 Inducers—Amprenavir—acquired immunodeficiency syndrome	0.0981	0.156	CiPCiCtD
Dabrafenib—SLC22A6—Stavudine—acquired immunodeficiency syndrome	0.0204	0.0784	CbGbCtD
Dabrafenib—SLC22A6—Didanosine—acquired immunodeficiency syndrome	0.0155	0.0594	CbGbCtD
Dabrafenib—SLCO1B1—Indinavir—acquired immunodeficiency syndrome	0.015	0.0577	CbGbCtD
Dabrafenib—SLCO1B1—Nelfinavir—acquired immunodeficiency syndrome	0.0146	0.056	CbGbCtD
Dabrafenib—SLCO1B1—Saquinavir—acquired immunodeficiency syndrome	0.0132	0.0506	CbGbCtD
Dabrafenib—SLCO1B1—Ritonavir—acquired immunodeficiency syndrome	0.0132	0.0506	CbGbCtD
Dabrafenib—SLC22A8—Zidovudine—acquired immunodeficiency syndrome	0.0117	0.0448	CbGbCtD
Dabrafenib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0116	0.0445	CbGbCtD
Dabrafenib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0105	0.0402	CbGbCtD
Dabrafenib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0105	0.0402	CbGbCtD
Dabrafenib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.01	0.0386	CbGbCtD
Dabrafenib—SLC22A6—Zidovudine—acquired immunodeficiency syndrome	0.00812	0.0312	CbGbCtD
Dabrafenib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.00776	0.0298	CbGbCtD
Dabrafenib—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.00736	0.0283	CbGbCtD
Dabrafenib—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.00736	0.0283	CbGbCtD
Dabrafenib—SLC22A6—Lamivudine—acquired immunodeficiency syndrome	0.00628	0.0242	CbGbCtD
Dabrafenib—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.00558	0.0214	CbGbCtD
Dabrafenib—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.00558	0.0214	CbGbCtD
Dabrafenib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.00551	0.0212	CbGbCtD
Dabrafenib—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.00535	0.0205	CbGbCtD
Dabrafenib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.00498	0.0191	CbGbCtD
Dabrafenib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0043	0.0165	CbGbCtD
Dabrafenib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.00417	0.016	CbGbCtD
Dabrafenib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.00377	0.0145	CbGbCtD
Dabrafenib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.00377	0.0145	CbGbCtD
Dabrafenib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.00362	0.0139	CbGbCtD
Dabrafenib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.00351	0.0135	CbGbCtD
Dabrafenib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0033	0.0127	CbGbCtD
Dabrafenib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0033	0.0127	CbGbCtD
Dabrafenib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.00298	0.0115	CbGbCtD
Dabrafenib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.00298	0.0115	CbGbCtD
Dabrafenib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0028	0.0108	CbGbCtD
Dabrafenib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00258	0.0099	CbGbCtD
Dabrafenib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0025	0.00961	CbGbCtD
Dabrafenib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00226	0.00869	CbGbCtD
Dabrafenib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00226	0.00869	CbGbCtD
Dabrafenib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00217	0.00833	CbGbCtD
Dabrafenib—NEK11—lung—acquired immunodeficiency syndrome	0.00102	0.0478	CbGeAlD
Dabrafenib—LIMK1—blood—acquired immunodeficiency syndrome	0.000832	0.039	CbGeAlD
Dabrafenib—LIMK1—vagina—acquired immunodeficiency syndrome	0.000771	0.0362	CbGeAlD
Dabrafenib—NEK11—brain—acquired immunodeficiency syndrome	0.000721	0.0338	CbGeAlD
Dabrafenib—SLCO1B1—blood plasma—acquired immunodeficiency syndrome	0.000699	0.0328	CbGeAlD
Dabrafenib—NEK11—lymph node—acquired immunodeficiency syndrome	0.000697	0.0327	CbGeAlD
Dabrafenib—SIK1—skin of body—acquired immunodeficiency syndrome	0.000565	0.0265	CbGeAlD
Dabrafenib—LIMK1—brain—acquired immunodeficiency syndrome	0.000516	0.0242	CbGeAlD
Dabrafenib—BRAF—blood—acquired immunodeficiency syndrome	0.000514	0.0241	CbGeAlD
Dabrafenib—LIMK1—lymph node—acquired immunodeficiency syndrome	0.000499	0.0234	CbGeAlD
Dabrafenib—BRAF—bone marrow—acquired immunodeficiency syndrome	0.000497	0.0233	CbGeAlD
Dabrafenib—BRAF—vagina—acquired immunodeficiency syndrome	0.000476	0.0223	CbGeAlD
Dabrafenib—SIK1—lymphoid tissue—acquired immunodeficiency syndrome	0.000457	0.0214	CbGeAlD
Dabrafenib—BRAF—lung—acquired immunodeficiency syndrome	0.000451	0.0211	CbGeAlD
Dabrafenib—RAF1—skin of body—acquired immunodeficiency syndrome	0.000449	0.0211	CbGeAlD
Dabrafenib—SIK1—blood—acquired immunodeficiency syndrome	0.00043	0.0202	CbGeAlD
Dabrafenib—SIK1—bone marrow—acquired immunodeficiency syndrome	0.000416	0.0195	CbGeAlD
Dabrafenib—SIK1—spinal cord—acquired immunodeficiency syndrome	0.000414	0.0194	CbGeAlD
Dabrafenib—SLCO1B3—vagina—acquired immunodeficiency syndrome	0.000411	0.0193	CbGeAlD
Dabrafenib—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000398	0.0186	CbGeAlD
Dabrafenib—SLCO1B3—lung—acquired immunodeficiency syndrome	0.000388	0.0182	CbGeAlD
Dabrafenib—SIK1—lung—acquired immunodeficiency syndrome	0.000377	0.0177	CbGeAlD
Dabrafenib—RAF1—lymphoid tissue—acquired immunodeficiency syndrome	0.000364	0.0171	CbGeAlD
Dabrafenib—RAF1—digestive system—acquired immunodeficiency syndrome	0.000359	0.0169	CbGeAlD
Dabrafenib—SIK1—nervous system—acquired immunodeficiency syndrome	0.000349	0.0164	CbGeAlD
Dabrafenib—RAF1—blood—acquired immunodeficiency syndrome	0.000342	0.0161	CbGeAlD
Dabrafenib—SIK1—central nervous system—acquired immunodeficiency syndrome	0.000336	0.0158	CbGeAlD
Dabrafenib—RAF1—bone marrow—acquired immunodeficiency syndrome	0.000331	0.0155	CbGeAlD
Dabrafenib—RAF1—spinal cord—acquired immunodeficiency syndrome	0.00033	0.0155	CbGeAlD
Dabrafenib—BRAF—brain—acquired immunodeficiency syndrome	0.000319	0.015	CbGeAlD
Dabrafenib—RAF1—vagina—acquired immunodeficiency syndrome	0.000317	0.0149	CbGeAlD
Dabrafenib—BRAF—lymph node—acquired immunodeficiency syndrome	0.000308	0.0144	CbGeAlD
Dabrafenib—RAF1—lung—acquired immunodeficiency syndrome	0.0003	0.0141	CbGeAlD
Dabrafenib—RAF1—nervous system—acquired immunodeficiency syndrome	0.000278	0.013	CbGeAlD
Dabrafenib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000269	0.0126	CbGeAlD
Dabrafenib—SLCO1B1—digestive system—acquired immunodeficiency syndrome	0.000269	0.0126	CbGeAlD
Dabrafenib—RAF1—central nervous system—acquired immunodeficiency syndrome	0.000268	0.0125	CbGeAlD
Dabrafenib—SIK1—brain—acquired immunodeficiency syndrome	0.000267	0.0125	CbGeAlD
Dabrafenib—SIK1—lymph node—acquired immunodeficiency syndrome	0.000258	0.0121	CbGeAlD
Dabrafenib—SLCO1B1—blood—acquired immunodeficiency syndrome	0.000256	0.012	CbGeAlD
Dabrafenib—RAF1—brain—acquired immunodeficiency syndrome	0.000212	0.00996	CbGeAlD
Dabrafenib—SLC22A6—brain—acquired immunodeficiency syndrome	0.000206	0.00967	CbGeAlD
Dabrafenib—RAF1—lymph node—acquired immunodeficiency syndrome	0.000205	0.00963	CbGeAlD
Dabrafenib—SLC22A8—blood—acquired immunodeficiency syndrome	0.000199	0.00933	CbGeAlD
Dabrafenib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000191	0.00894	CbGeAlD
Dabrafenib—SLC22A8—nervous system—acquired immunodeficiency syndrome	0.000162	0.00758	CbGeAlD
Dabrafenib—SLC22A8—central nervous system—acquired immunodeficiency syndrome	0.000156	0.00729	CbGeAlD
Dabrafenib—CYP2C8—blood—acquired immunodeficiency syndrome	0.000146	0.00683	CbGeAlD
Dabrafenib—ABCG2—blood—acquired immunodeficiency syndrome	0.000142	0.00664	CbGeAlD
Dabrafenib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000137	0.00643	CbGeAlD
Dabrafenib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000136	0.0064	CbGeAlD
Dabrafenib—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000135	0.00633	CbGeAlD
Dabrafenib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000131	0.00616	CbGeAlD
Dabrafenib—ABCG2—lung—acquired immunodeficiency syndrome	0.000124	0.00582	CbGeAlD
Dabrafenib—SLC22A8—brain—acquired immunodeficiency syndrome	0.000124	0.00579	CbGeAlD
Dabrafenib—ABCB1—retina—acquired immunodeficiency syndrome	0.000104	0.0049	CbGeAlD
Dabrafenib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000104	0.00486	CbGeAlD
Dabrafenib—CYP3A4—blood—acquired immunodeficiency syndrome	9.87e-05	0.00463	CbGeAlD
Dabrafenib—CYP2C8—brain—acquired immunodeficiency syndrome	9.04e-05	0.00424	CbGeAlD
Dabrafenib—ABCG2—brain—acquired immunodeficiency syndrome	8.79e-05	0.00412	CbGeAlD
Dabrafenib—ABCG2—lymph node—acquired immunodeficiency syndrome	8.49e-05	0.00398	CbGeAlD
Dabrafenib—CYP3A4—nervous system—acquired immunodeficiency syndrome	8.01e-05	0.00376	CbGeAlD
Dabrafenib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	7.71e-05	0.00362	CbGeAlD
Dabrafenib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	7.42e-05	0.00348	CbGeAlD
Dabrafenib—ABCB1—digestive system—acquired immunodeficiency syndrome	7.33e-05	0.00344	CbGeAlD
Dabrafenib—ABCB1—blood—acquired immunodeficiency syndrome	6.98e-05	0.00327	CbGeAlD
Dabrafenib—ABCB1—bone marrow—acquired immunodeficiency syndrome	6.76e-05	0.00317	CbGeAlD
Dabrafenib—ABCB1—spinal cord—acquired immunodeficiency syndrome	6.73e-05	0.00315	CbGeAlD
Dabrafenib—ABCB1—vagina—acquired immunodeficiency syndrome	6.47e-05	0.00304	CbGeAlD
Dabrafenib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	6.25e-05	0.000824	CcSEcCtD
Dabrafenib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	6.24e-05	0.000823	CcSEcCtD
Dabrafenib—Insomnia—Zidovudine—acquired immunodeficiency syndrome	6.23e-05	0.000822	CcSEcCtD
Dabrafenib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	6.22e-05	0.000821	CcSEcCtD
Dabrafenib—Chills—Lamivudine—acquired immunodeficiency syndrome	6.21e-05	0.000819	CcSEcCtD
Dabrafenib—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	6.2e-05	0.000817	CcSEcCtD
Dabrafenib—Cough—Delavirdine—acquired immunodeficiency syndrome	6.19e-05	0.000817	CcSEcCtD
Dabrafenib—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	6.19e-05	0.000816	CcSEcCtD
Dabrafenib—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	6.18e-05	0.000814	CcSEcCtD
Dabrafenib—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	6.17e-05	0.000814	CcSEcCtD
Dabrafenib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	6.17e-05	0.000814	CcSEcCtD
Dabrafenib—Hypertension—Delavirdine—acquired immunodeficiency syndrome	6.13e-05	0.000808	CcSEcCtD
Dabrafenib—ABCB1—lung—acquired immunodeficiency syndrome	6.12e-05	0.00287	CbGeAlD
Dabrafenib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	6.12e-05	0.000807	CcSEcCtD
Dabrafenib—Back pain—Saquinavir—acquired immunodeficiency syndrome	6.11e-05	0.000806	CcSEcCtD
Dabrafenib—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000801	CcSEcCtD
Dabrafenib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	6.07e-05	0.0008	CcSEcCtD
Dabrafenib—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	6.05e-05	0.000798	CcSEcCtD
Dabrafenib—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	6.04e-05	0.000797	CcSEcCtD
Dabrafenib—Myalgia—Delavirdine—acquired immunodeficiency syndrome	6.04e-05	0.000797	CcSEcCtD
Dabrafenib—Erythema—Lamivudine—acquired immunodeficiency syndrome	6.03e-05	0.000795	CcSEcCtD
Dabrafenib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	6.03e-05	0.000795	CcSEcCtD
Dabrafenib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	5.99e-05	0.00079	CcSEcCtD
Dabrafenib—Nausea—Amprenavir—acquired immunodeficiency syndrome	5.95e-05	0.000785	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	5.95e-05	0.000784	CcSEcCtD
Dabrafenib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	5.94e-05	0.000783	CcSEcCtD
Dabrafenib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	5.94e-05	0.000783	CcSEcCtD
Dabrafenib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	5.93e-05	0.000782	CcSEcCtD
Dabrafenib—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	5.91e-05	0.000779	CcSEcCtD
Dabrafenib—Constipation—Zidovudine—acquired immunodeficiency syndrome	5.89e-05	0.000777	CcSEcCtD
Dabrafenib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	5.89e-05	0.000777	CcSEcCtD
Dabrafenib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	5.88e-05	0.000775	CcSEcCtD
Dabrafenib—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	5.88e-05	0.000775	CcSEcCtD
Dabrafenib—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	5.86e-05	0.000772	CcSEcCtD
Dabrafenib—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	5.85e-05	0.000772	CcSEcCtD
Dabrafenib—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	5.84e-05	0.00077	CcSEcCtD
Dabrafenib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	5.84e-05	0.00077	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	5.84e-05	0.00077	CcSEcCtD
Dabrafenib—Back pain—Lamivudine—acquired immunodeficiency syndrome	5.83e-05	0.000769	CcSEcCtD
Dabrafenib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	5.81e-05	0.000766	CcSEcCtD
Dabrafenib—Vomiting—Didanosine—acquired immunodeficiency syndrome	5.81e-05	0.000766	CcSEcCtD
Dabrafenib—Insomnia—Indinavir—acquired immunodeficiency syndrome	5.8e-05	0.000764	CcSEcCtD
Dabrafenib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	5.8e-05	0.000764	CcSEcCtD
Dabrafenib—Oedema—Delavirdine—acquired immunodeficiency syndrome	5.79e-05	0.000764	CcSEcCtD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	5.78e-05	0.00454	CbGpPWpGaD
Dabrafenib—Rash—Didanosine—acquired immunodeficiency syndrome	5.76e-05	0.000759	CcSEcCtD
Dabrafenib—Infection—Delavirdine—acquired immunodeficiency syndrome	5.76e-05	0.000759	CcSEcCtD
Dabrafenib—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	5.75e-05	0.000759	CcSEcCtD
Dabrafenib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	5.75e-05	0.000758	CcSEcCtD
Dabrafenib—RAF1—IL-5 Signaling Pathway—IL2—acquired immunodeficiency syndrome	5.73e-05	0.0045	CbGpPWpGaD
Dabrafenib—Cough—Ritonavir—acquired immunodeficiency syndrome	5.73e-05	0.000755	CcSEcCtD
Dabrafenib—Headache—Didanosine—acquired immunodeficiency syndrome	5.72e-05	0.000754	CcSEcCtD
Dabrafenib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	5.71e-05	0.000752	CcSEcCtD
Dabrafenib—Asthenia—Stavudine—acquired immunodeficiency syndrome	5.69e-05	0.00075	CcSEcCtD
Dabrafenib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	5.67e-05	0.000748	CcSEcCtD
Dabrafenib—ABCB1—nervous system—acquired immunodeficiency syndrome	5.67e-05	0.00266	CbGeAlD
Dabrafenib—RAF1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	5.67e-05	0.00445	CbGpPWpGaD
Dabrafenib—Hypertension—Ritonavir—acquired immunodeficiency syndrome	5.67e-05	0.000747	CcSEcCtD
Dabrafenib—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	5.66e-05	0.000746	CcSEcCtD
Dabrafenib—RAF1—SOS-mediated signalling—IL6—acquired immunodeficiency syndrome	5.64e-05	0.00443	CbGpPWpGaD
Dabrafenib—RAF1—GRB2 events in EGFR signaling—IL6—acquired immunodeficiency syndrome	5.64e-05	0.00443	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	5.64e-05	0.000743	CcSEcCtD
Dabrafenib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	5.63e-05	0.000742	CcSEcCtD
Dabrafenib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	5.63e-05	0.000742	CcSEcCtD
Dabrafenib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	5.62e-05	0.000741	CcSEcCtD
Dabrafenib—Pruritus—Stavudine—acquired immunodeficiency syndrome	5.61e-05	0.00074	CcSEcCtD
Dabrafenib—Asthenia—Abacavir—acquired immunodeficiency syndrome	5.6e-05	0.000739	CcSEcCtD
Dabrafenib—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	5.6e-05	0.000738	CcSEcCtD
Dabrafenib—Myalgia—Ritonavir—acquired immunodeficiency syndrome	5.59e-05	0.000737	CcSEcCtD
Dabrafenib—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	5.59e-05	0.000737	CcSEcCtD
Dabrafenib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	5.57e-05	0.000734	CcSEcCtD
Dabrafenib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	5.57e-05	0.000734	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	5.55e-05	0.000732	CcSEcCtD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	5.55e-05	0.00436	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	5.53e-05	0.000729	CcSEcCtD
Dabrafenib—Pruritus—Abacavir—acquired immunodeficiency syndrome	5.53e-05	0.000729	CcSEcCtD
Dabrafenib—Fatigue—Indinavir—acquired immunodeficiency syndrome	5.53e-05	0.000728	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	5.52e-05	0.000727	CcSEcCtD
Dabrafenib—Cough—Saquinavir—acquired immunodeficiency syndrome	5.51e-05	0.000727	CcSEcCtD
Dabrafenib—RAF1—IL-2 Signaling Pathway—IL2—acquired immunodeficiency syndrome	5.51e-05	0.00433	CbGpPWpGaD
Dabrafenib—Constipation—Indinavir—acquired immunodeficiency syndrome	5.48e-05	0.000723	CcSEcCtD
Dabrafenib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	5.48e-05	0.000722	CcSEcCtD
Dabrafenib—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	5.47e-05	0.000721	CcSEcCtD
Dabrafenib—ABCB1—central nervous system—acquired immunodeficiency syndrome	5.46e-05	0.00256	CbGeAlD
Dabrafenib—Hypertension—Saquinavir—acquired immunodeficiency syndrome	5.45e-05	0.000719	CcSEcCtD
Dabrafenib—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	5.45e-05	0.000718	CcSEcCtD
Dabrafenib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	5.45e-05	0.000718	CcSEcCtD
Dabrafenib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	5.44e-05	0.000717	CcSEcCtD
Dabrafenib—RAF1—SHC1 events in EGFR signaling—IL6—acquired immunodeficiency syndrome	5.43e-05	0.00427	CbGpPWpGaD
Dabrafenib—RAF1—Signalling to p38 via RIT and RIN—IL6—acquired immunodeficiency syndrome	5.43e-05	0.00427	CbGpPWpGaD
Dabrafenib—RAF1—SHC-mediated signalling—IL6—acquired immunodeficiency syndrome	5.43e-05	0.00427	CbGpPWpGaD
Dabrafenib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	5.42e-05	0.000715	CcSEcCtD
Dabrafenib—Nausea—Didanosine—acquired immunodeficiency syndrome	5.42e-05	0.000715	CcSEcCtD
Dabrafenib—Hypotension—Delavirdine—acquired immunodeficiency syndrome	5.41e-05	0.000714	CcSEcCtD
Dabrafenib—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	5.4e-05	0.000711	CcSEcCtD
Dabrafenib—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	5.38e-05	0.000709	CcSEcCtD
Dabrafenib—Myalgia—Saquinavir—acquired immunodeficiency syndrome	5.38e-05	0.000709	CcSEcCtD
Dabrafenib—Oedema—Ritonavir—acquired immunodeficiency syndrome	5.36e-05	0.000706	CcSEcCtD
Dabrafenib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	5.34e-05	0.000705	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	5.34e-05	0.000704	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.28e-05	0.000696	CcSEcCtD
Dabrafenib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.26e-05	0.000694	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	5.26e-05	0.00413	CbGpPWpGaD
Dabrafenib—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	5.26e-05	0.000694	CcSEcCtD
Dabrafenib—Cough—Lamivudine—acquired immunodeficiency syndrome	5.26e-05	0.000693	CcSEcCtD
Dabrafenib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.26e-05	0.000693	CcSEcCtD
Dabrafenib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.25e-05	0.000693	CcSEcCtD
Dabrafenib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.25e-05	0.000692	CcSEcCtD
Dabrafenib—RAF1—ARMS-mediated activation—IL6—acquired immunodeficiency syndrome	5.24e-05	0.00412	CbGpPWpGaD
Dabrafenib—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.24e-05	0.000691	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.24e-05	0.000691	CcSEcCtD
Dabrafenib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.24e-05	0.000691	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.23e-05	0.000689	CcSEcCtD
Dabrafenib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.22e-05	0.000688	CcSEcCtD
Dabrafenib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.22e-05	0.000688	CcSEcCtD
Dabrafenib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.2e-05	0.000686	CcSEcCtD
Dabrafenib—RAF1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	5.18e-05	0.00407	CbGpPWpGaD
Dabrafenib—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.18e-05	0.000683	CcSEcCtD
Dabrafenib—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.18e-05	0.000683	CcSEcCtD
Dabrafenib—Rash—Nevirapine—acquired immunodeficiency syndrome	5.18e-05	0.000683	CcSEcCtD
Dabrafenib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.17e-05	0.000682	CcSEcCtD
Dabrafenib—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.16e-05	0.000681	CcSEcCtD
Dabrafenib—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.16e-05	0.00068	CcSEcCtD
Dabrafenib—Headache—Nevirapine—acquired immunodeficiency syndrome	5.14e-05	0.000678	CcSEcCtD
Dabrafenib—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.13e-05	0.000677	CcSEcCtD
Dabrafenib—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.13e-05	0.000677	CcSEcCtD
Dabrafenib—Infection—Saquinavir—acquired immunodeficiency syndrome	5.12e-05	0.000675	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	5.1e-05	0.000672	CcSEcCtD
Dabrafenib—RAF1—IL2-mediated signaling events—IFNG—acquired immunodeficiency syndrome	5.07e-05	0.00399	CbGpPWpGaD
Dabrafenib—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	5.07e-05	0.000668	CcSEcCtD
Dabrafenib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	5.07e-05	0.000668	CcSEcCtD
Dabrafenib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.000667	CcSEcCtD
Dabrafenib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	5.06e-05	0.000667	CcSEcCtD
Dabrafenib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	5.05e-05	0.000666	CcSEcCtD
Dabrafenib—Vomiting—Stavudine—acquired immunodeficiency syndrome	5.04e-05	0.000665	CcSEcCtD
Dabrafenib—RAF1—Interleukin-2 signaling—IL2—acquired immunodeficiency syndrome	5.04e-05	0.00396	CbGpPWpGaD
Dabrafenib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	5.04e-05	0.000664	CcSEcCtD
Dabrafenib—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	5.02e-05	0.000662	CcSEcCtD
Dabrafenib—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.01e-05	0.000661	CcSEcCtD
Dabrafenib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.01e-05	0.00066	CcSEcCtD
Dabrafenib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.01e-05	0.00066	CcSEcCtD
Dabrafenib—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.01e-05	0.00066	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5e-05	0.000659	CcSEcCtD
Dabrafenib—Rash—Stavudine—acquired immunodeficiency syndrome	5e-05	0.000659	CcSEcCtD
Dabrafenib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	4.99e-05	0.000659	CcSEcCtD
Dabrafenib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	4.99e-05	0.000658	CcSEcCtD
Dabrafenib—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	4.99e-05	0.000657	CcSEcCtD
Dabrafenib—Headache—Nelfinavir—acquired immunodeficiency syndrome	4.98e-05	0.000657	CcSEcCtD
Dabrafenib—RAF1—Signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	4.97e-05	0.00391	CbGpPWpGaD
Dabrafenib—Headache—Stavudine—acquired immunodeficiency syndrome	4.97e-05	0.000655	CcSEcCtD
Dabrafenib—Vomiting—Abacavir—acquired immunodeficiency syndrome	4.97e-05	0.000655	CcSEcCtD
Dabrafenib—Constipation—Delavirdine—acquired immunodeficiency syndrome	4.95e-05	0.000653	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	4.95e-05	0.000653	CcSEcCtD
Dabrafenib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	4.94e-05	0.000652	CcSEcCtD
Dabrafenib—Rash—Abacavir—acquired immunodeficiency syndrome	4.92e-05	0.000649	CcSEcCtD
Dabrafenib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	4.92e-05	0.000649	CcSEcCtD
Dabrafenib—Oedema—Lamivudine—acquired immunodeficiency syndrome	4.92e-05	0.000649	CcSEcCtD
Dabrafenib—RAF1—SHC-related events—IL6—acquired immunodeficiency syndrome	4.91e-05	0.00385	CbGpPWpGaD
Dabrafenib—RAF1—Frs2-mediated activation—IL6—acquired immunodeficiency syndrome	4.91e-05	0.00385	CbGpPWpGaD
Dabrafenib—RAF1—SHC-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	4.91e-05	0.00385	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—CSF2—acquired immunodeficiency syndrome	4.9e-05	0.00385	CbGpPWpGaD
Dabrafenib—Headache—Abacavir—acquired immunodeficiency syndrome	4.89e-05	0.000645	CcSEcCtD
Dabrafenib—Infection—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.000644	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	4.88e-05	0.000644	CcSEcCtD
Dabrafenib—Nausea—Nevirapine—acquired immunodeficiency syndrome	4.88e-05	0.000643	CcSEcCtD
Dabrafenib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	4.88e-05	0.000643	CcSEcCtD
Dabrafenib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	4.85e-05	0.000639	CcSEcCtD
Dabrafenib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	4.82e-05	0.000636	CcSEcCtD
Dabrafenib—Hypotension—Saquinavir—acquired immunodeficiency syndrome	4.82e-05	0.000635	CcSEcCtD
Dabrafenib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	4.82e-05	0.000635	CcSEcCtD
Dabrafenib—RAF1—SHP2 signaling—IFNG—acquired immunodeficiency syndrome	4.79e-05	0.00376	CbGpPWpGaD
Dabrafenib—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	4.79e-05	0.000631	CcSEcCtD
Dabrafenib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	4.79e-05	0.000631	CcSEcCtD
Dabrafenib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	4.78e-05	0.00063	CcSEcCtD
Dabrafenib—SIK1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	4.76e-05	0.00374	CbGpPWpGaD
Dabrafenib—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	4.76e-05	0.000627	CcSEcCtD
Dabrafenib—LIMK1—Immune System—ACTG1—acquired immunodeficiency syndrome	4.76e-05	0.00374	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Leptin—IL6—acquired immunodeficiency syndrome	4.75e-05	0.00374	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	4.74e-05	0.000625	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	4.74e-05	0.00372	CbGpPWpGaD
Dabrafenib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	4.72e-05	0.000623	CcSEcCtD
Dabrafenib—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	4.72e-05	0.000623	CcSEcCtD
Dabrafenib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	4.71e-05	0.000622	CcSEcCtD
Dabrafenib—Nausea—Stavudine—acquired immunodeficiency syndrome	4.71e-05	0.000621	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	4.7e-05	0.000619	CcSEcCtD
Dabrafenib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	4.66e-05	0.000615	CcSEcCtD
Dabrafenib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	4.66e-05	0.000614	CcSEcCtD
Dabrafenib—Nausea—Abacavir—acquired immunodeficiency syndrome	4.64e-05	0.000612	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	4.63e-05	0.00061	CcSEcCtD
Dabrafenib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	4.62e-05	0.000609	CcSEcCtD
Dabrafenib—RAF1—Prolonged ERK activation events—IL6—acquired immunodeficiency syndrome	4.61e-05	0.00362	CbGpPWpGaD
Dabrafenib—Asthenia—Indinavir—acquired immunodeficiency syndrome	4.6e-05	0.000606	CcSEcCtD
Dabrafenib—Hypotension—Lamivudine—acquired immunodeficiency syndrome	4.6e-05	0.000606	CcSEcCtD
Dabrafenib—Constipation—Ritonavir—acquired immunodeficiency syndrome	4.58e-05	0.000604	CcSEcCtD
Dabrafenib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	4.58e-05	0.000604	CcSEcCtD
Dabrafenib—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	4.58e-05	0.000604	CcSEcCtD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—CXCR4—acquired immunodeficiency syndrome	4.57e-05	0.00359	CbGpPWpGaD
Dabrafenib—ABCB1—HIF-1-alpha transcription factor network—CXCL12—acquired immunodeficiency syndrome	4.57e-05	0.00359	CbGpPWpGaD
Dabrafenib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	4.56e-05	0.000601	CcSEcCtD
Dabrafenib—Pruritus—Indinavir—acquired immunodeficiency syndrome	4.53e-05	0.000598	CcSEcCtD
Dabrafenib—BRAF—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	4.51e-05	0.00354	CbGpPWpGaD
Dabrafenib—RAF1—IL2-mediated signaling events—IL2—acquired immunodeficiency syndrome	4.51e-05	0.00354	CbGpPWpGaD
Dabrafenib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	4.48e-05	0.000591	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	4.48e-05	0.000591	CcSEcCtD
Dabrafenib—RAF1—Axon guidance—ACTG1—acquired immunodeficiency syndrome	4.48e-05	0.00352	CbGpPWpGaD
Dabrafenib—RAF1—SHC1 events in ERBB4 signaling—IL6—acquired immunodeficiency syndrome	4.48e-05	0.00352	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	4.46e-05	0.000588	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000587	CcSEcCtD
Dabrafenib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	4.45e-05	0.000587	CcSEcCtD
Dabrafenib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	4.45e-05	0.000586	CcSEcCtD
Dabrafenib—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.41e-05	0.000581	CcSEcCtD
Dabrafenib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.38e-05	0.000578	CcSEcCtD
Dabrafenib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.38e-05	0.000578	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.38e-05	0.000578	CcSEcCtD
Dabrafenib—Rash—Zidovudine—acquired immunodeficiency syndrome	4.34e-05	0.000573	CcSEcCtD
Dabrafenib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.34e-05	0.000573	CcSEcCtD
Dabrafenib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.34e-05	0.000572	CcSEcCtD
Dabrafenib—ABCB1—brain—acquired immunodeficiency syndrome	4.33e-05	0.00203	CbGeAlD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IFNG—acquired immunodeficiency syndrome	4.32e-05	0.00339	CbGpPWpGaD
Dabrafenib—Headache—Zidovudine—acquired immunodeficiency syndrome	4.32e-05	0.000569	CcSEcCtD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	4.31e-05	0.00338	CbGpPWpGaD
Dabrafenib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.28e-05	0.000565	CcSEcCtD
Dabrafenib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.28e-05	0.000564	CcSEcCtD
Dabrafenib—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.27e-05	0.000563	CcSEcCtD
Dabrafenib—RAF1—SHP2 signaling—IL2—acquired immunodeficiency syndrome	4.26e-05	0.00334	CbGpPWpGaD
Dabrafenib—BRAF—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	4.25e-05	0.00334	CbGpPWpGaD
Dabrafenib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.25e-05	0.00056	CcSEcCtD
Dabrafenib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.24e-05	0.000559	CcSEcCtD
Dabrafenib—RAF1—GRB2 events in ERBB2 signaling—IL6—acquired immunodeficiency syndrome	4.24e-05	0.00333	CbGpPWpGaD
Dabrafenib—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.24e-05	0.000559	CcSEcCtD
Dabrafenib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.24e-05	0.000558	CcSEcCtD
Dabrafenib—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.24e-05	0.000558	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.22e-05	0.000556	CcSEcCtD
Dabrafenib—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.21e-05	0.000555	CcSEcCtD
Dabrafenib—ABCB1—lymph node—acquired immunodeficiency syndrome	4.19e-05	0.00196	CbGeAlD
Dabrafenib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.16e-05	0.000548	CcSEcCtD
Dabrafenib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.14e-05	0.000546	CcSEcCtD
Dabrafenib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.1e-05	0.00054	CcSEcCtD
Dabrafenib—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.09e-05	0.00054	CcSEcCtD
Dabrafenib—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.08e-05	0.000537	CcSEcCtD
Dabrafenib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.08e-05	0.000537	CcSEcCtD
Dabrafenib—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.07e-05	0.000537	CcSEcCtD
Dabrafenib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	4.04e-05	0.00318	CbGpPWpGaD
Dabrafenib—Rash—Indinavir—acquired immunodeficiency syndrome	4.04e-05	0.000533	CcSEcCtD
Dabrafenib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.04e-05	0.000532	CcSEcCtD
Dabrafenib—RAF1—SHC1 events in ERBB2 signaling—IL6—acquired immunodeficiency syndrome	4.03e-05	0.00316	CbGpPWpGaD
Dabrafenib—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.02e-05	0.00053	CcSEcCtD
Dabrafenib—Headache—Indinavir—acquired immunodeficiency syndrome	4.01e-05	0.000529	CcSEcCtD
Dabrafenib—RAF1—TWEAK Signaling Pathway—TNF—acquired immunodeficiency syndrome	4.01e-05	0.00315	CbGpPWpGaD
Dabrafenib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4e-05	0.000528	CcSEcCtD
Dabrafenib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	3.96e-05	0.000523	CcSEcCtD
Dabrafenib—ABCB1—Allograft Rejection—CXCL12—acquired immunodeficiency syndrome	3.96e-05	0.00311	CbGpPWpGaD
Dabrafenib—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	3.95e-05	0.00052	CcSEcCtD
Dabrafenib—LIMK1—Immune System—MBL2—acquired immunodeficiency syndrome	3.91e-05	0.00307	CbGpPWpGaD
Dabrafenib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	3.89e-05	0.000513	CcSEcCtD
Dabrafenib—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	3.89e-05	0.000513	CcSEcCtD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.88e-05	0.00305	CbGpPWpGaD
Dabrafenib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	3.85e-05	0.000508	CcSEcCtD
Dabrafenib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	3.84e-05	0.000507	CcSEcCtD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IL2—acquired immunodeficiency syndrome	3.84e-05	0.00302	CbGpPWpGaD
Dabrafenib—RAF1—Signalling to RAS—IL6—acquired immunodeficiency syndrome	3.84e-05	0.00301	CbGpPWpGaD
Dabrafenib—RAF1—VEGFR2 mediated cell proliferation—IL6—acquired immunodeficiency syndrome	3.84e-05	0.00301	CbGpPWpGaD
Dabrafenib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	3.83e-05	0.000505	CcSEcCtD
Dabrafenib—Rash—Efavirenz—acquired immunodeficiency syndrome	3.82e-05	0.000503	CcSEcCtD
Dabrafenib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	3.81e-05	0.000503	CcSEcCtD
Dabrafenib—Nausea—Indinavir—acquired immunodeficiency syndrome	3.81e-05	0.000502	CcSEcCtD
Dabrafenib—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	3.8e-05	0.000501	CcSEcCtD
Dabrafenib—Headache—Efavirenz—acquired immunodeficiency syndrome	3.79e-05	0.0005	CcSEcCtD
Dabrafenib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	3.79e-05	0.0005	CcSEcCtD
Dabrafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.73e-05	0.00293	CbGpPWpGaD
Dabrafenib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	3.7e-05	0.000488	CcSEcCtD
Dabrafenib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	3.68e-05	0.000486	CcSEcCtD
Dabrafenib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	3.67e-05	0.000483	CcSEcCtD
Dabrafenib—Rash—Delavirdine—acquired immunodeficiency syndrome	3.65e-05	0.000482	CcSEcCtD
Dabrafenib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	3.65e-05	0.000481	CcSEcCtD
Dabrafenib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	3.65e-05	0.000481	CcSEcCtD
Dabrafenib—Headache—Delavirdine—acquired immunodeficiency syndrome	3.63e-05	0.000479	CcSEcCtD
Dabrafenib—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	3.62e-05	0.000478	CcSEcCtD
Dabrafenib—RAF1—Ceramide signaling pathway—TNF—acquired immunodeficiency syndrome	3.61e-05	0.00283	CbGpPWpGaD
Dabrafenib—Nausea—Efavirenz—acquired immunodeficiency syndrome	3.6e-05	0.000474	CcSEcCtD
Dabrafenib—LIMK1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	3.57e-05	0.0028	CbGpPWpGaD
Dabrafenib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	3.54e-05	0.000467	CcSEcCtD
Dabrafenib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.53e-05	0.000465	CcSEcCtD
Dabrafenib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.53e-05	0.000465	CcSEcCtD
Dabrafenib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.000459	CcSEcCtD
Dabrafenib—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.44e-05	0.000454	CcSEcCtD
Dabrafenib—RAF1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.43e-05	0.00269	CbGpPWpGaD
Dabrafenib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.41e-05	0.00045	CcSEcCtD
Dabrafenib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.41e-05	0.000449	CcSEcCtD
Dabrafenib—Rash—Ritonavir—acquired immunodeficiency syndrome	3.38e-05	0.000445	CcSEcCtD
Dabrafenib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.37e-05	0.000445	CcSEcCtD
Dabrafenib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.37e-05	0.000444	CcSEcCtD
Dabrafenib—Headache—Ritonavir—acquired immunodeficiency syndrome	3.36e-05	0.000442	CcSEcCtD
Dabrafenib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.28e-05	0.000432	CcSEcCtD
Dabrafenib—RAF1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	3.26e-05	0.00256	CbGpPWpGaD
Dabrafenib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.25e-05	0.000429	CcSEcCtD
Dabrafenib—Rash—Saquinavir—acquired immunodeficiency syndrome	3.25e-05	0.000429	CcSEcCtD
Dabrafenib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.25e-05	0.000428	CcSEcCtD
Dabrafenib—RAF1—TWEAK Signaling Pathway—IL6—acquired immunodeficiency syndrome	3.24e-05	0.00255	CbGpPWpGaD
Dabrafenib—RAF1—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	3.24e-05	0.00254	CbGpPWpGaD
Dabrafenib—Headache—Saquinavir—acquired immunodeficiency syndrome	3.23e-05	0.000426	CcSEcCtD
Dabrafenib—RAF1—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	3.2e-05	0.00251	CbGpPWpGaD
Dabrafenib—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.18e-05	0.00042	CcSEcCtD
Dabrafenib—RAF1—FCERI mediated MAPK activation—IL6—acquired immunodeficiency syndrome	3.18e-05	0.0025	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	3.17e-05	0.00249	CbGpPWpGaD
Dabrafenib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.13e-05	0.000412	CcSEcCtD
Dabrafenib—RAF1—FRS2-mediated cascade—IL6—acquired immunodeficiency syndrome	3.12e-05	0.00245	CbGpPWpGaD
Dabrafenib—RAF1—Signalling to ERKs—IL6—acquired immunodeficiency syndrome	3.12e-05	0.00245	CbGpPWpGaD
Dabrafenib—Rash—Lamivudine—acquired immunodeficiency syndrome	3.1e-05	0.000409	CcSEcCtD
Dabrafenib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.1e-05	0.000409	CcSEcCtD
Dabrafenib—Headache—Lamivudine—acquired immunodeficiency syndrome	3.08e-05	0.000406	CcSEcCtD
Dabrafenib—LIMK1—Immune System—CCR2—acquired immunodeficiency syndrome	3.06e-05	0.00241	CbGpPWpGaD
Dabrafenib—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.06e-05	0.000404	CcSEcCtD
Dabrafenib—SLCO1B3—Metabolism—TAT—acquired immunodeficiency syndrome	3.03e-05	0.00238	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL10—acquired immunodeficiency syndrome	3e-05	0.00236	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—CD40LG—acquired immunodeficiency syndrome	3e-05	0.00236	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	2.98e-05	0.00234	CbGpPWpGaD
Dabrafenib—BRAF—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.98e-05	0.00234	CbGpPWpGaD
Dabrafenib—RAF1—Interleukin-2 signaling—IL6—acquired immunodeficiency syndrome	2.96e-05	0.00233	CbGpPWpGaD
Dabrafenib—RAF1—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	2.94e-05	0.00231	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.93e-05	0.0023	CbGpPWpGaD
Dabrafenib—Nausea—Lamivudine—acquired immunodeficiency syndrome	2.92e-05	0.000385	CcSEcCtD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNA1—acquired immunodeficiency syndrome	2.92e-05	0.0023	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL4—acquired immunodeficiency syndrome	2.92e-05	0.00229	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—HLA-B—acquired immunodeficiency syndrome	2.85e-05	0.00224	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	2.82e-05	0.00222	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—acquired immunodeficiency syndrome	2.8e-05	0.0022	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—CSF2—acquired immunodeficiency syndrome	2.76e-05	0.00217	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNA1—acquired immunodeficiency syndrome	2.76e-05	0.00217	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD79A—acquired immunodeficiency syndrome	2.68e-05	0.0021	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL2—acquired immunodeficiency syndrome	2.59e-05	0.00203	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—AGPS—acquired immunodeficiency syndrome	2.57e-05	0.00202	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CCNT1—acquired immunodeficiency syndrome	2.53e-05	0.00199	CbGpPWpGaD
Dabrafenib—RAF1—SHP2 signaling—IL6—acquired immunodeficiency syndrome	2.5e-05	0.00197	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MBL2—acquired immunodeficiency syndrome	2.32e-05	0.00182	CbGpPWpGaD
Dabrafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	2.31e-05	0.00181	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—CSF2—acquired immunodeficiency syndrome	2.29e-05	0.0018	CbGpPWpGaD
Dabrafenib—BRAF—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	2.25e-05	0.00177	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.23e-05	0.00175	CbGpPWpGaD
Dabrafenib—SLCO1B3—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	2.22e-05	0.00174	CbGpPWpGaD
Dabrafenib—RAF1—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	2.2e-05	0.00173	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—acquired immunodeficiency syndrome	2.2e-05	0.00173	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD40LG—acquired immunodeficiency syndrome	2.18e-05	0.00172	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD8A—acquired immunodeficiency syndrome	2.16e-05	0.0017	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CSF2—acquired immunodeficiency syndrome	2.16e-05	0.0017	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—TNF—acquired immunodeficiency syndrome	2.14e-05	0.00168	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.13e-05	0.00167	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—HLA-B—acquired immunodeficiency syndrome	2.08e-05	0.00163	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.08e-05	0.00163	CbGpPWpGaD
Dabrafenib—RAF1—Disease—APOBEC3G—acquired immunodeficiency syndrome	2.06e-05	0.00162	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—TAT—acquired immunodeficiency syndrome	2.03e-05	0.0016	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.02e-05	0.00159	CbGpPWpGaD
Dabrafenib—SLC22A8—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	1.96e-05	0.00154	CbGpPWpGaD
Dabrafenib—BRAF—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.91e-05	0.0015	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—TAT—acquired immunodeficiency syndrome	1.88e-05	0.00148	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	1.88e-05	0.00148	CbGpPWpGaD
Dabrafenib—RAF1—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	1.84e-05	0.00145	CbGpPWpGaD
Dabrafenib—LIMK1—Axon guidance—IL6—acquired immunodeficiency syndrome	1.83e-05	0.00144	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IFNA1—acquired immunodeficiency syndrome	1.82e-05	0.00143	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CCR2—acquired immunodeficiency syndrome	1.82e-05	0.00143	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—ALB—acquired immunodeficiency syndrome	1.8e-05	0.00141	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events—IL6—acquired immunodeficiency syndrome	1.79e-05	0.00141	CbGpPWpGaD
Dabrafenib—RAF1—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	1.78e-05	0.0014	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.77e-05	0.00139	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.77e-05	0.00139	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	1.76e-05	0.00139	CbGpPWpGaD
Dabrafenib—RAF1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	1.76e-05	0.00138	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCNT1—acquired immunodeficiency syndrome	1.75e-05	0.00138	CbGpPWpGaD
Dabrafenib—RAF1—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	1.73e-05	0.00136	CbGpPWpGaD
Dabrafenib—RAF1—TNF alpha Signaling Pathway—IL6—acquired immunodeficiency syndrome	1.73e-05	0.00136	CbGpPWpGaD
Dabrafenib—RAF1—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	1.73e-05	0.00136	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.73e-05	0.00136	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ACTG1—acquired immunodeficiency syndrome	1.64e-05	0.00129	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	1.64e-05	0.00129	CbGpPWpGaD
Dabrafenib—SLC22A6—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	1.64e-05	0.00129	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.62e-05	0.00127	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.6e-05	0.00126	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.6e-05	0.00126	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.59e-05	0.00125	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	1.57e-05	0.00123	CbGpPWpGaD
Dabrafenib—RAF1—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	1.56e-05	0.00122	CbGpPWpGaD
Dabrafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	1.53e-05	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	1.53e-05	0.0012	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Interleukins—IL6—acquired immunodeficiency syndrome	1.52e-05	0.0012	CbGpPWpGaD
Dabrafenib—SLCO1B1—SLC-mediated transmembrane transport—ALB—acquired immunodeficiency syndrome	1.49e-05	0.00117	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.48e-05	0.00116	CbGpPWpGaD
Dabrafenib—RAF1—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	1.46e-05	0.00115	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	1.45e-05	0.00114	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	1.44e-05	0.00113	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—CSF2—acquired immunodeficiency syndrome	1.42e-05	0.00112	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	1.36e-05	0.00107	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MBL2—acquired immunodeficiency syndrome	1.35e-05	0.00106	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CXCR4—acquired immunodeficiency syndrome	1.33e-05	0.00104	CbGpPWpGaD
Dabrafenib—RAF1—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	1.32e-05	0.00104	CbGpPWpGaD
Dabrafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.31e-05	0.00103	CbGpPWpGaD
Dabrafenib—LIMK1—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.3e-05	0.00102	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IFNG—acquired immunodeficiency syndrome	1.28e-05	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.28e-05	0.00101	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	1.25e-05	0.000978	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—CD4—acquired immunodeficiency syndrome	1.24e-05	0.000974	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	1.23e-05	0.000969	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	1.23e-05	0.000967	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	1.23e-05	0.000966	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.23e-05	0.000964	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.23e-05	0.000964	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	1.21e-05	0.000949	CbGpPWpGaD
Dabrafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.2e-05	0.000939	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.18e-05	0.000931	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	1.18e-05	0.00093	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	1.18e-05	0.000924	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—TAT—acquired immunodeficiency syndrome	1.17e-05	0.000918	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.16e-05	0.000911	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	1.16e-05	0.00091	CbGpPWpGaD
Dabrafenib—LIMK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000904	CbGpPWpGaD
Dabrafenib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	1.14e-05	0.000897	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL2—acquired immunodeficiency syndrome	1.14e-05	0.000896	CbGpPWpGaD
Dabrafenib—SLCO1B3—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.13e-05	0.000885	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.11e-05	0.000871	CbGpPWpGaD
Dabrafenib—RAF1—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	1.11e-05	0.000869	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	1.1e-05	0.000864	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.1e-05	0.00086	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	1.09e-05	0.00086	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.09e-05	0.000857	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.09e-05	0.000857	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 signaling—IL6—acquired immunodeficiency syndrome	1.09e-05	0.000856	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CCR2—acquired immunodeficiency syndrome	1.06e-05	0.000833	CbGpPWpGaD
Dabrafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	1.02e-05	0.000805	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	1.02e-05	0.000805	CbGpPWpGaD
Dabrafenib—RAF1—DAP12 interactions—IL6—acquired immunodeficiency syndrome	1.02e-05	0.000805	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	1.02e-05	0.000799	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	1.02e-05	0.000798	CbGpPWpGaD
Dabrafenib—BRAF—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.01e-05	0.000793	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	1.01e-05	0.000791	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	1e-05	0.000787	CbGpPWpGaD
Dabrafenib—SLC22A8—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	9.97e-06	0.000783	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—AGPS—acquired immunodeficiency syndrome	9.93e-06	0.00078	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.9e-06	0.000778	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNA1—acquired immunodeficiency syndrome	9.54e-06	0.00075	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	9.31e-06	0.000732	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	9.31e-06	0.000732	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—ALB—acquired immunodeficiency syndrome	9.28e-06	0.000729	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD79A—acquired immunodeficiency syndrome	9.26e-06	0.000728	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CXCR4—acquired immunodeficiency syndrome	9.2e-06	0.000723	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CCR5—acquired immunodeficiency syndrome	9.11e-06	0.000716	CbGpPWpGaD
Dabrafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	9.08e-06	0.000713	CbGpPWpGaD
Dabrafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	8.77e-06	0.000689	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	8.65e-06	0.00068	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.32e-06	0.000654	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	8.3e-06	0.000652	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	8.17e-06	0.000642	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	8.03e-06	0.000631	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.96e-06	0.000625	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	7.58e-06	0.000595	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.57e-06	0.000595	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—acquired immunodeficiency syndrome	7.55e-06	0.000593	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—acquired immunodeficiency syndrome	7.53e-06	0.000591	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	7.48e-06	0.000587	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CSF2—acquired immunodeficiency syndrome	7.47e-06	0.000587	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—acquired immunodeficiency syndrome	7.47e-06	0.000587	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—acquired immunodeficiency syndrome	7.36e-06	0.000579	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-B—acquired immunodeficiency syndrome	7.18e-06	0.000564	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	7.1e-06	0.000558	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	7.08e-06	0.000557	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	7.07e-06	0.000556	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	7.01e-06	0.000551	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	6.98e-06	0.000549	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.98e-06	0.000548	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	6.85e-06	0.000538	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—acquired immunodeficiency syndrome	6.71e-06	0.000527	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	6.44e-06	0.000506	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	6.44e-06	0.000506	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.38e-06	0.000501	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—acquired immunodeficiency syndrome	6.32e-06	0.000496	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—acquired immunodeficiency syndrome	6.31e-06	0.000495	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	6.27e-06	0.000493	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—acquired immunodeficiency syndrome	5.72e-06	0.00045	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.64e-06	0.000443	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—acquired immunodeficiency syndrome	5.59e-06	0.000439	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	5.33e-06	0.000419	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—acquired immunodeficiency syndrome	5.28e-06	0.000414	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.9e-06	0.000385	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.83e-06	0.000379	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.57e-06	0.000359	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—acquired immunodeficiency syndrome	4.51e-06	0.000354	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—acquired immunodeficiency syndrome	4.44e-06	0.000349	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.42e-06	0.000347	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.32e-06	0.000339	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—acquired immunodeficiency syndrome	4.29e-06	0.000337	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.98e-06	0.000313	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—acquired immunodeficiency syndrome	3.96e-06	0.000311	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—acquired immunodeficiency syndrome	3.95e-06	0.00031	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.79e-06	0.000298	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.69e-06	0.00029	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—acquired immunodeficiency syndrome	3.54e-06	0.000278	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	3.28e-06	0.000258	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—acquired immunodeficiency syndrome	3.1e-06	0.000243	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.55e-06	0.0002	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.54e-06	0.000199	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—acquired immunodeficiency syndrome	2.32e-06	0.000182	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.17e-06	0.00017	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—acquired immunodeficiency syndrome	2.14e-06	0.000168	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	2.04e-06	0.00016	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	1.77e-06	0.000139	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.5e-06	0.000118	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	1.09e-06	8.59e-05	CbGpPWpGaD
